Generate Biomedicines, Inc. (GENB)
NASDAQ: GENB · Real-Time Price · USD
12.65
-3.35 (-20.94%)
At close: Feb 27, 2026, 4:00 PM EST
11.78
-0.87 (-6.88%)
After-hours: Feb 27, 2026, 7:59 PM EST
Generate Biomedicines Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 |
| Revenue | 31.89 | 20.46 |
| Revenue Growth (YoY) | 55.89% | - |
| Cost of Revenue | 224.7 | 175.31 |
| Gross Profit | -192.81 | -154.85 |
| Selling, General & Admin | 42.26 | 42.09 |
| Operating Expenses | 42.26 | 42.09 |
| Operating Income | -235.07 | -196.94 |
| Interest Expense | -1.14 | -2.12 |
| Interest & Investment Income | 13.66 | 18.12 |
| Currency Exchange Gain (Loss) | -0.15 | -0.08 |
| Other Non Operating Income (Expenses) | -0.11 | -0.15 |
| Pretax Income | -222.8 | -181.17 |
| Income Tax Expense | 0.16 | 0.21 |
| Earnings From Continuing Operations | -222.97 | -181.38 |
| Minority Interest in Earnings | 19.81 | 7.61 |
| Net Income | -203.15 | -173.77 |
| Preferred Dividends & Other Adjustments | 46.37 | 40.01 |
| Net Income to Common | -249.52 | -213.78 |
| Shares Outstanding (Basic) | 50 | 49 |
| Shares Outstanding (Diluted) | 50 | 49 |
| Shares Change (YoY) | 2.77% | - |
| EPS (Basic) | -4.98 | -4.39 |
| EPS (Diluted) | -4.98 | -4.39 |
| Free Cash Flow | -204.13 | -121.2 |
| Free Cash Flow Per Share | -4.08 | -2.49 |
| Operating Margin | -737.04% | -962.60% |
| Profit Margin | -782.38% | -1044.90% |
| Free Cash Flow Margin | -640.06% | -592.39% |
| EBITDA | -221.89 | -181.59 |
| D&A For EBITDA | 13.18 | 15.35 |
| EBIT | -235.07 | -196.94 |
Source: S&P Capital IQ. Standard template.
Financial Sources.